Drug updated on 7/25/2024
| Dosage Form | Injection (intravenous; 100 mg/10 mL [10 mg/mL], 500 mg/50 mL [10 mg/mL]) |
| Drug Class | Human vascular endothelial growth factor receptor 2 antagonists |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated as a single agent or in combination with paclitaxel, for treatment of advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma with disease progression on or after prior fluoropyrimidine- or platinum-containing chemotherapy.
- Indicated in combination with erlotinib, for first-line treatment of metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) mutations.
- Indicated in combination with docetaxel, for treatment of metastatic non-small cell lung cancer with disease progression on or after platinum-based chemotherapy. Patients with EGFR or ALK genomic tumor aberrations should have disease progression on FDA-approved therapy for these aberrations prior to receiving CYRAMZA.
- Indicated in combination with FOLFIRI, for the treatment of metastatic colorectal cancer with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine.
- Indicated as a single agent, for the treatment of hepatocellular carcinoma in patients who have an alpha fetoprotein of ≥400 ng/mL and have been treated with sorafenib.
Latest News
Summary
- Ramucirumab (Cyramza) is indicated for the treatment of advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma, metastatic non-small cell lung cancer (NSCLC), metastatic colorectal cancer, and hepatocellular carcinoma.
- The information was derived from 15 systematic reviews and meta-analyses documents.
- In NSCLC patients treated with ramucirumab plus docetaxel, significant improvements in overall survival (OS), progression-free survival (PFS), and overall response rate (ORR) were observed compared to placebo plus docetaxel.
- For NSCLC with EGFR mutations, combination treatments such as erlotinib + ramucirumab showed comparative effectiveness with osimertinib and dacomitinib; however, newer combinations like osimertinib + bevacizumab often ranked higher for PFS benefits.
- In hepatocellular carcinoma patients with alpha-fetoprotein ≥400 ng/mL previously treated with sorafenib, ramucirumab demonstrated improved survival across various liver disease etiologies while maintaining a consistent safety profile across subgroups.
- For second-line therapy in gastric or gastro-esophageal junction cancer patients who progressed after prior chemotherapy regimens containing fluoropyrimidine or platinum agents, ramucirumab combined with chemotherapy significantly improved OS compared to chemotherapy alone.
- Network meta-analysis insights revealed that although immunotherapies frequently dominated rankings for safety and efficacy in treating NSCLC post-immunotherapy failure scenarios, the combination of ramucirumab and docetaxel remained an effective subsequent therapy option irrespective of previous immune checkpoint inhibitor treatment history.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Cyramza (ramucirumab) prescribing information. | 2022 | FDA |